|Dr. Peter G. Traber M.D.||Chief Exec. Officer, Pres, Chief Medical Officer and Director||733.94k||N/A||62|
|Mr. Jack W. Callicutt CPA||Chief Financial Officer||363.27k||N/A||50|
|Dr. Harold H. Shlevin Ph.D.||Chief Operating Officer and Corp. Sec.||359.04k||N/A||67|
|Dr. Eliezer Zomer Ph.D.||VP of Discovery Research and Product Devel.||N/A||N/A||70|
|Mr. Steven Schubert||VP of Fin.||N/A||N/A||N/A|
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The companys lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.
Galectin Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.